TLDR:
- Guangzhou Baiyunshan Pharmaceutical Holdings Company has restructured a partnership agreement, introducing the State-owned Enterprise Innovation Fund as a new partner to the GP Venture Capital Fund.
- The investment ratio has been altered, and the GP Fund’s contribution has been reduced from RMB 690 million to RMB 390 million.
Guangzhou Baiyunshan Pharmaceutical Holdings Company (HK:0874) has announced a restructuring of its venture capital partnership agreement. The company has introduced the State-owned Enterprise Innovation Fund as a new partner to the GP Venture Capital Fund. As part of the agreement modification, the investment ratio has been adjusted, and the GP Fund’s contribution has been reduced from RMB 690 million to RMB 390 million. Despite these changes, the core provisions of the agreement remain unchanged. This connected transaction has been performed in compliance with the Hong Kong Listing Rules and does not require independent shareholder approval.
This update provides investors with insight into the recent developments at Guangzhou Baiyunshan Pharmaceutical Holdings Company. For more information on HK:0874 stock, investors can refer to TipRanks’ Stock Analysis page.
